Tomorrow is an important NR first thing in the morning followed by media conference.

Notice of Conference Call & Media Advisory: Theratechnologies reports 52-week confirmatory Phase 3 results

(Marketwire via COMTEX News Network) -- Theratechnologies (TSX: TH) advises of an upcoming conference call and webcast to discuss the 52-week results of its confirmatory Phase 3 clinical trial, testing tesamorelin, in patients with HIV-associated lipodystrophy. The call will be moderated by Dr. Andrea Gilpin, Vice President, IR & Communications, at Theratechnologies. Mr. Yves Rosconi, President and CEO, Mr. Luc Tanguay, Senior Executive Vice President and CFO, Dr. Pierre Caudrelier, Chief Medical Officer and Dr. Christian Marsolais, Vice President, Clinical Research, will also be participating. The conference call will take place tomorrow, December 15, 2008, at 8:00 a.m. Eastern Standard Time. Prior to the call, a press release will be issued around 7:00 a.m. December 15, 2008 Conference Call and Webcast For the conference call, interested participants are asked to dial the following numbers: 416-644-3418 or 1-800-732-9303 (toll free). Please call five minutes prior to the conference in order to ensure your participation. The webcast will be accessible at the following links: www.investorcalendar.com and www.theratech.com. A replay of the conference call will be available from December 15, 2008 at 10:00 a.m. to December 22, 2008 at 11:59 p.m. at the following number: 416-640-1917, pass code 21292496# or 1-877-289-8525, code 2129496#.